Edition:
India

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

178.95USD
19 Jul 2018
Change (% chg)

$-0.60 (-0.33%)
Prev Close
$179.55
Open
$179.30
Day's High
$181.15
Day's Low
$178.60
Volume
139,815
Avg. Vol
263,112
52-wk High
$236.05
52-wk Low
$85.90

Select another date:

Mon, May 14 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $2.31

* BLUEBIRD BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.

* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES

BRIEF-Bluebird Bio Reports Q4 Loss Per Share $2.52‍​

* BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority

* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY

Select another date: